BioAtla (BCAB)
NASDAQ:BCAB
US Market

BioAtla (BCAB) Stock Price & Analysis

117 Followers

BCAB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.24 - $12.15
Previous Close$3.15
Volume276.49K
Average Volume (3M)499.25K
Market Cap
$144.43M
Enterprise Value-$44.65M
Total Cash (Recent Filing)$192.69M
Total Debt (Recent Filing)$3.61M
Price to Earnings (P/E)-1.2
Beta2.08
Aug 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.66
Shares Outstanding47,667,516
10 Day Avg. Volume293,753
30 Day Avg. Volume499,247
Standard Deviation0.40
R-Squared0.00106
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.40
Forecast
Price Target Upside276.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.

---

BCAB FAQ

What was BioAtla’s price range in the past 12 months?
BioAtla lowest stock price was $2.23 and its highest was $12.15 in the past 12 months.
    What is BioAtla’s market cap?
    Currently, no data Available
    When is BioAtla’s upcoming earnings report date?
    BioAtla’s upcoming earnings report date is Aug 10, 2023 which is in 69 days.
      How were BioAtla’s earnings last quarter?
      BioAtla released its earnings results on May 11, 2023. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.604 by $0.024.
        Is BioAtla overvalued?
        According to Wall Street analysts BioAtla’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does BioAtla pay dividends?
          BioAtla does not currently pay dividends.
          What is BioAtla’s EPS estimate?
          BioAtla’s EPS estimate is -$0.66.
            How many shares outstanding does BioAtla have?
            BioAtla has 47,667,515 shares outstanding.
              What happened to BioAtla’s price movement after its last earnings report?
              BioAtla reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.604. Following the earnings report the stock price went up 14.33%.
                Which hedge fund is a major shareholder of BioAtla?
                Among the largest hedge funds holding BioAtla’s share is Woodline Partners LP. It holds BioAtla’s shares valued at N/A.

                  ---

                  BioAtla Stock Smart Score

                  The BioAtla stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  BioAtla

                  BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

                  ---

                  Top 5 ETFs holding BCAB

                  Name
                  Market Value
                  Smart Score
                  iShares NASDAQ US Biotechnology UCITS ETF
                  $67.83K
                  8
                  Invesco Nasdaq Biotechnology ETF
                  $2.77K
                  8
                  iShares Core S&P Total U.S. Stock Market ETF
                  $139.05
                  8
                  Up to five ETFs with an Outperform Smart Score that hold BCAB. The ETFs are listed according to market value of BCAB within the ETF

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Compass Therapeutics
                  Kezar Life Sciences
                  Coherus Biosciences
                  Caribou Biosciences

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis